Dermatology Times Newsletter

To view this email as a web page, click here.

Molecular assays have been proven to assist in the diagnosis and prognosis of malignant melanoma. One expert expects that these molecular assays will play a central role in the future treatment and management of malignant melanoma. See what they have to say in this article.

New dosing regimen for nivolumab plus ipilimumab

Among advanced melanoma patients in the CheckMate 511 phase IIIb/IV trial, raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg leads to a better safety profile without compromising efficacy. These results may offer patients with advanced melanoma a safer dosing regimen of nivolumab and ipilimumab. Read more here.

Immunotherapy efficacy in men vs women

This study explores the association between patient sex and the efficacy of immunotherapy on overall survival for the treatment of advanced solid tumors, including melanoma. Here’s what researchers found.

From our Latest Issue

First inductees to Dermatology Hall of Fame announced

Verrica’s cantharidin solution passes phase three trials

Don't ignore these coding changes in 2019

JOB OPPORTUNITIES

CA - Contour Dermatology & Cosmetic Surgery Center

CA - Integrated Dermatology

CO - Integrated Dermatology

CO-Integrated Dermatology

CT - Integrated Dermatology

MA - Integrated Dermatology

District of Columbia-Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

National - Integrated Dermatology

PA - Milton S Hershey Medical Center

NJ - Integrated Dermatology

NV - Integrated Dermatology

PA - Milton S Hershey Medical Center

PA - St. Luke's Physician Group

TN-Integrated Dermatology

VA - Integrated Dermatology

VT - Integrated Dermatology

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.